KLSE (MYR): GENTING (3182)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
4.77
Today's Change
+0.08 (1.71%)
Day's Change
4.75 - 4.87
Trading Volume
20,449,900
2024-06-23
2024-06-21
2024-06-21
2024-06-21
2024-06-21
2024-06-21
2024-06-20
2024-06-18
2024-06-18
2024-06-18
AngTayKor
1,735 posts
Posted by AngTayKor > 2023-05-18 01:04 | Report Abuse
Posted by AngTayKor > 2 months ago | Report Abuse
"Breaking: FDA neuroscience chief Billy Dunn, who led Aduhelm approval, will leave agency"
With FDA running into severe operating cash and funding issues a couple of years ago, most of these FDA officials (civil service) aspire to cross-over into large pharmas (private sector) as highly paid consultants for their own career advancement so there is always motivation to curry favour their potential future boss when they are on duty at the FDA.
----------------------------------
May 17, 2023 10:51 AM EDTUpdated 11:22 AM
Ex-FDA neuro chief Billy Dunn is taking a spin through the revolving door with biopharma — and that's a problem
It’s been less than three months since the FDA put out word that Billy Dunn had left the agency following a controversial run highlighted by a calamitous decision to approve Biogen’s Alzheimer’s drug, Aduhelm. And he didn’t leave much room for a break.
On Tuesday night we learned, via press release, that Prothena CEO Gene Kinney had signed him up for a lucrative board post, where no doubt Dunn can play a helpful role in guiding them through the FDA process as they advance their own neuro drugs through the clinic.